Yvonne Coyle is an Oncology physician. OpenAlex indexes 30 publications with 761 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3410 Worth St Ste 400
Dallas, TX 752462092
Telephone
214-370-1000Provider last certified this registry record 21 Sept 2022.
Clinical trials
- Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
Sponsor: US Oncology Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20252 payments
- ABBVIE INC.Program year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.5%PD-1 inhibitor30.1%Pembrolizumab100%Part B, office-administered≥22 patientsMicrotubule Inhibitor21.9%Paclitaxel100%Part B, office-administered≥19 patients+ 2 more classes in this area
Metabolism & gastrointestinal
39.1%Other antiemetics33.8%Fosaprepitant100%Part B, office-administered≥35 patientsSerotonin-3 Receptor Antagonist4.6%Palonosetron hcl60%Granisetron hydrochloride37%Ondansetron Odt3%Part D + Part B≥44 patients+ 4 more classes in this area
Sensory organs
4.2%Corticosteroid4.2%Dexamethasone sodium phosphate100%Part B, office-administered≥61 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1996–2002 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Lobular Carcinoma of the Breast with Gastrointestinal Metastasis
Baylor University Medical Center Proceedings
2015 - Model for the Cost-Efficient Delivery of Continuous Quality Cancer Care: A Hospital and Private-Practice Collaboration
Baylor University Medical Center Proceedings
2013
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”